Name: Ketoprofen
Brand: Selleck Chemicals
SKU: S1645
Availability: InStock
Rating: 5 (3 reviews)

Jump to

Quality Control

Batch: Purity: 100%

100

Related Targets	Adrenergic Receptor AChR 5-HT Receptor Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other COX Inhibitors	NS-398 (NS398) Paeoniflorin (NSC 178886) Xanthohumol Lumiracoxib Bufexamac Ginsenoside Rd Etoricoxib Oroxin B Nimesulide (-)-Epicatechin gallate

Solubility

In vitro
Batch:

DMSO : 51 mg/mL (200.56 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 51 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.5mg/ml (1.97mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.5mg/ml (1.97mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	254.28	Formula	C₁₆H₁₄O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	22071-15-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	RP-19583			SMILES	CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	COX-1 COX-2
In vitro	Ketoprofen combined with UVB irradiation induces the cytotoxicity and suppresses DNA synthesis in HaCaT cells in a concentration-dependent manner. This compound combined with UVB irradiation inhibits the cell growth and induces G2/M cell cycle arrest by modulating the levels of cdc2, cyclin B1, Chk1, Tyr15-phosphorylated cdc2 and p21. It also provokes a striking accumulation of cyclin B1-cdc2-p21 complexes, concomitantly with an increase in the levels of Tyr15-phosphorylated cdc2 and p21 protein. This chemical combined with UVB irradiation accentuates the apoptotic response to UVB radiation in HaCaT cells as evidenced by DAPI staining.
In vivo	Ketoprofen at 1% level in suitable topical vehicles can effectively inhibit GCF-LTB4 and GCF-PGE2 and positively alter alveolar bone activity in the ligature-induced model of periodontitis in the monkey. This compound (3.63 mg/kg bwt) reduces hoof pain andlameness to a greater extent than the 2.2 mg/kg dose and phenylbutazone. It is more effective than local anesthesia (LA), or caudal epidural anesthesia (EPI) in decreasing cortisol and partially reverses the reduction in average daily gain (ADG) following castration. This chemical (40 and 80 mg/kg diet) reduces the incidence of transitional cell carcinoma of the urinary bladder by >70% from that seen in dietary mice.
References	[1] https://pubmed.ncbi.nlm.nih.gov/17964538/ [2] https://pubmed.ncbi.nlm.nih.gov/8971650/ [3] https://pubmed.ncbi.nlm.nih.gov/8536666/ [4] https://pubmed.ncbi.nlm.nih.gov/12772856/ [5] https://pubmed.ncbi.nlm.nih.gov/8706245/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-24)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06912763	RECRUITING	Fibrosis Syndrome; Lymphedema; Head &Amp; Neck Cancer; Fibrosis	M.D. Anderson Cancer Center	2025-08-08	PHASE2
NCT05584046	RECRUITING	Plantar Fasciitis	Chinese University of Hong Kong	2023-09-20
NCT06731647	RECRUITING	Non-steroidal Anti-inflammatory Drugs; Pleurodesis; Pneumothorax; Pain Management	Centre Hospitalier Universitaire, Amiens	2025-02-01	PHASE2
NCT06381063	RECRUITING	Acute Postoperative Pain; Non-steroidal Anti-inflammatory Drugs; Cardiac Surgery; Pain Intensity; Multimodal Pain Management	Centre Hospitalier Universitaire, Amiens	2024-03-27	PHASE3
NCT07319728	ACTIVE_NOT_RECRUITING	Knee Osteoarthritis	New Valley University	2025-05-10	PHASE1
NCT07610265	COMPLETED	Post Endodontic Pain	Nims University Rajasthan	2024-04-18	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Ketoprofen COX inhibitor

Chemical Structure

Molecular Weight: 254.28